Crofelemer

Drug Overview

CROFELEMER, containing the active ingredient of the same name, is a first-in-class therapeutic agent in the Gastroenterology field and the Drug Class of ANTIDIARRHEALS. It is a botanical drug substance purified from the red sap (latex) of the Croton lechleri tree. It is specifically engineered as a Targeted Therapy for the management of chronic, watery diarrhea in patients living with HIV/AIDS, where the diarrhea is not caused by an infection.

• Generic Name: Crofelemer
• US Brand Names: Mytesi (formerly Fulyzaq)
• Route of Administration: Oral (Delayed-release tablets)
• FDA Approval Status: FDA-approved for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Crofelemer is a Small Molecule (proanthocyanidin oligomer) that remains almost entirely within the gastrointestinal tract with negligible systemic absorption. In international clinical protocols, it is valued for its unique “antisecretory” mechanism, which addresses the physiological imbalance of fluid transport across the Intestinal Epithelial Barrier without affecting intestinal motility or the absorption of antiretroviral medications.

What Is It and How Does It Work? (Mechanism of Action)

The effectiveness of Crofelemer in treating HIV/AIDS Associated Non-Infectious Diarrhea is due to its dual inhibitory effect on chloride ion channels in the intestinal lumen.

1. Regulation of Chloride Secretion

Diarrhea in HIV patients often results from the overactivation of chloride channels, which “pump” chloride ions into the gut. Water follows these ions to maintain osmotic balance, leading to watery stools. Crofelemer acts as a potent, non-systemic inhibitor of two specific channels:

• CFTR (Cystic Fibrosis Transmembrane Conductance Regulator): A cAMP-stimulated chloride channel.
• CaCC (Calcium-Activated Chloride Channel): A channel stimulated by calcium.

2. Restoration of Fluid Balance

By blocking these channels, Crofelemer reduces the excessive secretion of chloride ions and the subsequent flow of water into the intestinal tract. This helps to normalize the consistency of the stool and decrease the frequency of bowel movements.

3. Preservation of the Intestinal Epithelial Barrier

Unlike opioid-based antidiarrheals (like loperamide), Crofelemer does not slow down the “transit time” (peristalsis) of the gut. This is critical because it prevents the “pooling” of waste that can lead to bacterial overgrowth. By stabilizing fluid transport, it supports the integrity of the Intestinal Epithelial Barrier and helps maintain a stable Gut Microbiome.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for Crofelemer is:

• Non-Infectious Diarrhea in HIV/AIDS: Symptomatic relief in adult patients currently receiving antiretroviral therapy (ART).

Other Approved & Off-Label Uses

• Chemotherapy-Induced Diarrhea (Off-label): Investigational use for patients experiencing “secretory” diarrhea as a side effect of targeted cancer therapies (e.g., TKIs).
• Irritable Bowel Syndrome with Diarrhea (IBS-D) (Off-label): Potential use in patients where chloride channel overactivity is a suspected driver of symptoms.
• Functional Diarrhea (Off-label): Symptomatic management of chronic idiopathic watery stools.

Primary Gastroenterology Indications

• Secretory Diarrhea Management: Directly targeting the “pump” that causes fluid loss.
• Nutritional Stability: Helping patients retain fluids and electrolytes to improve overall weight and energy levels.
• ART Compliance Support: Reducing the GI side effects of HIV medications to ensure patients continue their life-saving antiretroviral regimens.

Dosage and Administration Protocols

Crofelemer is a delayed-release tablet that must be swallowed whole to ensure the botanical oligomers reach the intestines intact.

Dosage Adjustments and Specific Populations

• Delayed-Release Integrity: The tablets should not be crushed, chewed, or broken. Doing so will release the drug in the stomach, where it may be degraded by acid, rendering it ineffective.
• Pediatric Use: Safety and effectiveness in patients under 18 years of age have not been established.
• Elderly Patients: Generally follows adult dosing; however, Vigilance is required to monitor for dehydration or electrolyte shifts in frail populations.
• Renal/Hepatic Impairment: Because systemic absorption is minimal (nearly zero), no dosage adjustments are typically required for kidney or liver disease.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical efficacy is measured by the “Monthly Clinical Response,” defined as a significant reduction in the number of watery weekly bowel movements.

• Symptom Resolution: In pivotal Phase 3 trials (ADVENT study), patients receiving Crofelemer 125 mg twice daily achieved a clinical response rate twice as high as those on placebo.
• Long-Term Durability: Data (2020–2026) show that the antidiarrheal effect is maintained over 48 weeks of continuous therapy without the development of tolerance or “rebound” diarrhea.
• Safety Profile Efficacy: Clinical studies confirm that Crofelemer does not interact with common HIV medications (like Protease Inhibitors or RTIs), ensuring no loss of viral suppression.
• Mucosal Impact: Research indicates that by normalizing chloride flow, Crofelemer helps reduce the “leaky gut” inflammation markers often seen in the Intestinal Epithelial Barrier of HIV-positive individuals.

Safety Profile and Side Effects

There are no Black Box Warnings for Crofelemer. It is exceptionally well-tolerated due to its lack of systemic absorption.

Common Side Effects (>2%)

• Upper Respiratory Tract Infection: Reported in clinical trials, though the link to the drug is unclear.
• Bronchitis/Cough: Mild respiratory symptoms.
• Flatulence: Mild gas as the gut fluid balance adjusts.
• Increased Bilirubin: Rare and typically transient.

Serious Adverse Events

• Infection Masking: Before starting Crofelemer, clinicians must rule out infectious causes of diarrhea (e.g., C. difficile, Cryptosporidium, or CMV). Treating an infection with an antidiarrheal without antibiotics/antivirals can be dangerous.
• Hypersensitivity: Extremely rare allergic reactions to the botanical sap components.

Management Strategies

The most important strategy is the Infectious Workup. Crofelemer should only be used once “infectious diarrhea” has been ruled out. Vigilance is required regarding the tablet’s integrity; if a patient cannot swallow the tablet whole, an alternative therapy must be sought.

Research Areas

Current Research Areas focus on “Botanical Drug Development” and Mucosal Immunology.

Recent research (2024–2026) is investigating whether Crofelemer can be used to treat “Cancer-Related Malabsorption.” By stabilizing chloride channels, it may help the Intestinal Epithelial Barrier recover from the damage caused by modern Small Molecule oncology drugs.

Other active trials are evaluating the impact of Crofelemer on the Gut Microbiome. Some evidence suggests that by reducing the “washout” effect of chronic diarrhea, Crofelemer allows beneficial bacteria to recolonize the mucosal surface. Scientists are also exploring the use of Crofelemer in pediatric populations with rare secretory disorders (congenital chloride diarrhea).

Disclaimer: Research regarding the restoration of the gut microbiome via the reduction of the “washout” effect and the use of crofelemer for congenital chloride diarrhea is currently in the investigational phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Stool cultures and PCR tests are mandatory to rule out bacteria, viruses, or parasites.
• Organ Function: Minimal requirements due to lack of absorption, but a general CBC and Metabolic Panel are standard.
• Specialized Testing: Review the current ART regimen to ensure the diarrhea is likely a side effect of medication or HIV itself, rather than an opportunistic infection.
• Screening: Check for the patient’s ability to swallow delayed-release tablets whole.

Monitoring and Precautions

• Vigilance: Monitor for a “change in stool color” or the appearance of blood, which may indicate a new infection.
• Lifestyle: Emphasize hydration. While Crofelemer stops the “leak,” the patient must still replace lost fluids.
• Timing: Doses should be taken consistently every 12 hours to maintain constant channel inhibition.

“Do’s and Don’ts” list

• DO swallow the tablet whole with a full glass of water.
• DO continue your HIV medications exactly as prescribed while taking Crofelemer.
• DON’T crush, break, or chew the tablet.
• DON’T use this medication to treat “traveler’s diarrhea” or suspected food poisoning without a doctor’s guidance.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.